Skip to content
Review Open access

A Review of Driver Gene Co-mutations in Prognostic Stratification of Targeted Therapy for Non-Small Cell Lung Cancer

Oct 2026 · Theoretical and Natural Science · 0 citations

Abstract

EGFR-TKIs have significantly improved the survival outcomes of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, substantial heterogeneity in treatment efficacy exists among individuals, and conventional single-gene testing has limitations in guiding therapeutic decision-making. This systematic review focuses on the effects of driver gene co-mutations on the prognosis of targeted therapy in EGFR-mutant NSCLC and explores their value in clinical translation. Literature published from 2022 to 2026 concerning co-mutations and prognosis of targeted therapy in EGFR-mutant NSCLC was systematically retrieved from the PubMed database for summarization and analysis. This review found that TP53 is the most prevalent co-mutated gene in EGFR-mutant NSCLC and is strongly associated with poor prognosis under TKI monotherapy. Phase III clinical trials have confirmed that TKI combined with chemotherapy significantly prolongs median progression-free survival compared with TKI monotherapy among patients with EGFR mutations accompanied by tumor suppressor gene co-mutations. NGS multi-gene panels serve as the technical foundation for comprehensive co-mutation assessment. In summary, driver gene co-mutations play a critical role in prognostic stratification for EGFR-mutant NSCLC treatment. Taking co-mutation status into account helps identify high-risk patients who may benefit from intensified treatment, supporting more precise and individualized targeted therapy.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.